A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations

Rodrigo T. Calado, Joshua A. Regal, David E. Kleiner et al. · 2009

Read A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations by Rodrigo T. Calado, Joshua A. Regal, David E. Kleiner et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007926.txt.

Introduction

Rodrigo Calado and colleagues reported a family study of severe liver disease in PLOS ONE in 2009. They looked at faults in the genes that build telomerase, an enzyme that keeps the ends of chromosomes at a safe length. Such faults were already known to harm bone marrow.

In the families studied, the same kind of fault tracked with a wide range of grave liver problems. When telomeres grow too short, cells that divide often suffer first, and the liver proved no exception. The work widens the list of ills tied to worn chromosome ends and gives doctors a genetic clue when liver failure runs in a family.

Catalog record

CREATORRodrigo T. Calado, Joshua A. Regal, David E. Kleiner et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007926

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations Authors: Rodrigo T. Calado, Joshua A. Regal, David E. Kleiner, David S. Schrump, Nathan R. Peterson, Veronica Pons, Stephen J. Chanock, Peter M. Lansdorp, Neal S. Young Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0007926 ABSTRACT Telomerase is an enzyme specialized in maintaining telomere lengths in highly proliferative cells. Loss-of-function mutations cause critical telomere shortening and are associated with the bone marrow failure syndromes dyskeratosis congenita and aplastic anemia and with idiopathic pulmonary fibrosis. Here, we sought to determine the spectrum of clinical manifestations associated with telomerase loss-of-function mutations. Sixty-nine individuals from five unrelated families with a variety of hematologic, hepatic, and autoimmune disorders were screened for telomerase complex gene mutations; leukocyte telomere length was measured by flow fluorescence in situ hybridization in mutation carriers and some non-carriers; the effects of the identified mutations on telomerase activity were determined; and genetic and clinical data were correlated. In six generations of a large family, a loss-of-function mutation in the telomerase enzyme gene TERT associated with severe telomere shortening and a range of hematologic manifestations, from macrocytosis to acute myeloid leukemia, with severe liver diseases marked by fibrosis and inflammation, and one case of idiopathic pulmonary fibrosis but not with autoimmune disorders. Additionally, we identified four unrelated families in which loss-of-function TERC or TERT gene mutations tracked with marrow failure, pulmonary fibrosis, and a spectrum of liver disorders. These results indicate that heterozygous telomerase loss-of-function mutations associate with but are not determinant of a large spectrum of hematologic and liver abnormalities, with the latter sometimes occurring in the absence of marrow failure. Our findings, along with the link between pulmonary fibrosis and telomerase mutations, also suggest a common pathogenic mechanism for fibrotic diseases in which defective telomere repair plays important role. INTRODUCTION Telomeres consist of tandem TTAGGG repeats and associated proteins located at the ends of chromosomes that serve to prevent recombination, end-to-end fusion, and activation of DNA damage responses [1] . Telomere attrition occurs with each cell division as a result of DNA polymerase's inability to replicate the extreme 3′-end of template strands [2] , [3] . Progressive telomere shortening signals proliferation arrest and cellular senescence via p53, p21, and PMS2 [4] . In order to maintain proliferative capacity without compromising chromosome stability, embryonic and adult stem cells and certain somatic cells counter telomeric attrition by telomerase-catalyzed addition of TTAGGG repeats to the 3′ telomeric overhangs [5] . Constitutional loss-of-function telomerase mutations result in rapid telomere shortening and premature cellular senescence in proliferative somatic tissues [6] . Defective telomere repair has been causally associated with several human diseases. Genetic linkage analysis of the constitutional marrow failure syndrome dyskeratosis congenita led to the discovery of mutations in the genes DKC1 (which encodes dyskerin) [7] and telomerase RNA component (TERC) [8] . We reported mutations in TERC [9] and telomerase reverse transcriptase ( TERT ) [10] to be risk factors for apparently acquired aplastic anemia, a marrow failure disease occurring in patients who lack the typical physical anomalies and family history of dyskeratosis congenita. Mutations in telomerase complex genes also appear in families with idiopathic pulmonary fibrosis [11] – [13] , and pulmonary disease, esophageal stricture, malignancy, and liver disease also have been reported in twenty, seventeen, eight, and seven percent of dyskeratosis congenita patients, respectively [14] . Prior investigation of the clinical manifestations related to telomerase deficiency has been restricted to the screening of patient cohorts with specific diagnoses (bone marrow failure, pulmonary fibrosis). Using a different approach, we studied the family members of five unrelated patients with marrow failure and telomerase mutations; we genetically screened relatives who had a variety of hematologic, hepatic, and autoimmune disorders. We found that mutations were associated with a wide range of hematologic abnormalities, from macrocytosis to acute myeloid leukemia, and with severe liver diseases characterized by fibrosis, inflammation, and regeneration occurring independently of marrow failure or other affected organs. Idiopathic pulmonary fibrosis was diagnosed in one mutation-carrier individual. No other investigated illnesses tracked with mutational status. RESULTS The proband (Subject A-V-23; Fig. 1A ) presented at age twenty-five with a ten-year history of progressive pancytopenia ( Fig. 2A ). We have previously found that he was heterozygous for a loss-of-function TERT K570N mutation [15] . Eighteen members of his immediate family ( Fig. 1A , inset) were previously screened and eight tested positive for the mutation [15] . A long history of hematologic diseases was well known in the family back to the patient's paternal great-great-grandmother, Subject A-I-2, who died of an apparent blood disorder at the age of sixty-five. However, the great-grandmother and the grandfather, Subjects A-II-7 and A-III-16 (the latter previously found to be positive for the mutation [15] ), had not manifested hematologic symptoms. The proband's father (Subject A-IV-29) had thrombocytopenia and mild anemia from childhood. By age thirty-three, he developed myelodysplasia, which rapidly progressed to acute myeloid leukemia and death subsequent to an induction cycle of chemotherapy ( Fig. 2B ). The father was an obligatory carrier, as three of his sisters and his father also tested positive and his wife (the proband's mother) tested normal. Another of the proband's heterozygous paternal aunts (Subject A-IV-26) and the index patient's two heterozygous sisters, Subjects A-V-19 and A-V-20, ages forty-seven, twenty-two, and nineteen, respectively, only have macrocytosis, whereas his two wild-type sisters (Subjects A-V-21 and A-V-22) are healthy and without hematologic abnormalities. The patient's eldest of three sons, now six years old, carries the mutation, but he is asymptomatic and has normal blood counts. (A) The TERT K570N mutation tracked with hematological disorders and severe liver disease (lower pedigree) in Family A. In the extended family (upper pedigree), several disorders are found, including autoimmune diseases, anemia, thyroid diseases, liver diseases, and multiple miscarriages; however, the mutation was only associated with liver disease and multiple miscarriages. Two consanguineous relationships are not show: Subject A-IV-17 is a grand-daughter of Subjects A-II-7 and A-II-8, and Subject A-IV-7 is a grandson of Subjects A-III-14 and A-III-15. The genetic status for the immediate family (lower pedigree) and its association with bone marrow failure have been previously reported by us [15] . In smaller pedigrees, (B) TERC nucleotide 341-360 deletion tracked to liver disease in family B, (C) liver disease occurred in a family with a TERC nucleotide 28–34 deletion, and (D) in a family with TERC nucleotide 109–123 deletion. The following are denoted by their abbreviations: common variable immunodeficiency (CVID), aplastic anemia (AA), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), insulin-dependent diabetes mellitus (IDDM), systemic lupus erythematosus (SLE), idiopathic thrombocytic purpura (ITP), and non-alcoholic steatohepatitis (NASH). (A) Family A proband's bone marrow was hypocellular with isolated regions of normal cellularity (hematoxylin and eosin [H&E] staining; low power magnification). (B) Proband's father's bone marrow smear (Subject A-IV-29), illustrating dysplastic changes and increased number of blasts (H&E, high power magnification). (C) Subject A-IV-23's liver biopsy revealing islands of liver surrounded by zones of necrosis and parenchymal collapse (H&E, low magnification). The necrosis was far enough in the past that hepatocytes have mostly disappeared. In the inset, in some of the areas where hepatocytes were preserved there was still necrosis near the central veins. Little evidence of inflammation exists. (D) Subject's A-IV-25's

Read the complete text